<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of <z:hpo ids='HP_0011919'>pyothorax</z:hpo>-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e>) is reported </plain></SENT>
<SENT sid="1" pm="."><plain>A 76-year-old Japanese man developed a <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in the pleural cavity after 46 years duration of <z:hpo ids='HP_0011919'>pyothorax</z:hpo> due to <z:e sem="disease" ids="C0041327" disease_type="Disease or Syndrome" abbrv="">pulmonary tuberculosis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The histologic diagnosis of biopsy specimen was diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of B cell type </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells contained the monoclonal Epstein-Barr virus (EBV) determined by the analysis of terminal repeat of EBV genome and expressed EBV nuclear antigen 2 and latent membrane protein 1 (LMP1) </plain></SENT>
<SENT sid="4" pm="."><plain>He received <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> chemotherapy and was induced to complete remission (CR) </plain></SENT>
<SENT sid="5" pm="."><plain>After 19 months of CR, the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> developed again in the thoracic wall </plain></SENT>
<SENT sid="6" pm="."><plain>Histopathology and immunohistochemical phenotypes of <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrent tumor</z:e> were almost the same as those of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> with the exception of a little more frequent expression of LMP1 </plain></SENT>
<SENT sid="7" pm="."><plain>The EBV genome in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells was monoclonal, however, the clone was different from that of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>After <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> chemotherapy, minor EBV-positive clones in primary <z:hpo ids='HP_0002665'>lymphoma</z:hpo> might survive and develop into <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrent tumor</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e> starts as poly- or oligoclonal proliferation of B lineage cells </plain></SENT>
<SENT sid="10" pm="."><plain>This poly- or oligoclonality of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e> at the initial stage may suggest underlying immunosuppressive conditions in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PAL</z:e> </plain></SENT>
</text></document>